Global Paracetamol IV Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Paracetamol IV Market Research Report 2024
Paracetamol when given intravenously acts as an effective treatment option in relieving pain and gives rapid relief. Moreover, the use of intravenous paracetamol in combination with NSAIDs and narcotics has been gaining popularity and acceptance, which further propels the growth of the industry.
According to Mr Accuracy reports’s new survey, global Paracetamol IV market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Paracetamol IV market research.
Key companies engaged in the Paracetamol IV industry include Mallinckrodt (Mallinckrodt Pharmaceuticals), Cipla Inc., Lupin, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Novartis AG, Pfizer, Inc. and Abbott, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Paracetamol IV were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Paracetamol IV market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Paracetamol IV market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Mallinckrodt (Mallinckrodt Pharmaceuticals)
Cipla Inc.
Lupin
Dr. Reddy's Laboratories Ltd.
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.
Novartis AG
Pfizer, Inc.
Abbott
Sanofi
Bristol-Myers Squibb Company
Segment by Type
Pain
Pyrexia (Fever)
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Paracetamol IV report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Paracetamol IV market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Paracetamol IV market research.
Key companies engaged in the Paracetamol IV industry include Mallinckrodt (Mallinckrodt Pharmaceuticals), Cipla Inc., Lupin, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Novartis AG, Pfizer, Inc. and Abbott, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Paracetamol IV were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Paracetamol IV market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Paracetamol IV market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Mallinckrodt (Mallinckrodt Pharmaceuticals)
Cipla Inc.
Lupin
Dr. Reddy's Laboratories Ltd.
Aurobindo Pharma
Sun Pharmaceutical Industries Ltd.
Novartis AG
Pfizer, Inc.
Abbott
Sanofi
Bristol-Myers Squibb Company
Segment by Type
Pain
Pyrexia (Fever)
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Paracetamol IV report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source